Quantcast

Alopecia Pipeline Review, H1 2019 – Therapeutic Assessment of 28 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alopecia
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Alopecia – Pipeline Review, H1 2019, provides comprehensive information
on the therapeutics under development for Alopecia (Dermatology),
complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players
involved in therapeutic development for Alopecia and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II, Phase
I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5,
15, 5, 1, 16, 9 and 1 respectively. Similarly, the Universities
portfolio in Preclinical stages comprises 2 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Alopecia
    (Dermatology) by companies and universities/research institutes based
    on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Alopecia
    (Dermatology) therapeutics and enlists all their major and minor
    projects.
  • The pipeline guide evaluates Alopecia (Dermatology) therapeutics based
    on mechanism of action (MoA), drug target, route of administration
    (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Alopecia (Dermatology)

Key Topics Covered:

  1. Introduction
  2. Alopecia – Overview
  3. Alopecia – Therapeutics Development
  4. Alopecia – Therapeutics Assessment
  5. Alopecia – Companies Involved in Therapeutics Development
  6. Alopecia – Drug Profiles
  7. Alopecia – Dormant Projects
  8. Alopecia – Discontinued Products
  9. Alopecia – Product Development Milestones
  10. Appendix

Companies Mentioned

  • Aclaris Therapeutics Inc
  • Allergan Plc
  • Almirall SA
  • Berg LLC
  • BiologicsMD Inc
  • BirchBioMed Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Concert Pharmaceuticals Inc
  • Dong-A Socio Holdings Co Ltd
  • Eli Lilly and Co
  • Energenesis Biomedical Co Ltd
  • Follica Inc
  • Histogen Inc
  • Japan Tobacco Inc
  • JW Pharmaceutical Corp
  • Kuhnil Pharmaceutical Co Ltd
  • Lee’s Pharmaceutical Holdings Ltd
  • Nepsone ehf
  • OliX Pharmaceuticals Inc
  • Pfizer Inc
  • Phio Pharmaceuticals Corp
  • Portola Pharmaceuticals Inc
  • Quark Pharmaceuticals Inc
  • Samumed LLC
  • Suzhou Ribo Life Sciences Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Tigo GmbH

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4mx3cp/alopecia_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.